Our neglected cancers research

Our neglected cancers research

Garvan’s research into less common, high-mortality cancers is diverse, focusing on translating basic scientific discoveries into the clinic. These include defining the genetic characteristics of uncommon cancers, developing biomarkers of prognosis and therapeutic responsiveness, and understanding the molecular mechanisms of resistance to develop new personalised treatment strategies.

If you want to help make a difference, please support our cancer research.

Key areas of investigation

Prof David Thomas and his team
Prof David Thomas and his team

Molecular Screening and Therapeutics (MoST) Program

Professor David Thomas and his team have developed Molecular Screening and Therapeutics (MoST), an innovative clinical trials program, to evaluate the effectiveness of new treatments and help patients with high-mortality cancers.

‘The type of trial developed in the MoST program represents an important step forward in how we conduct trials for small patient populations.’

Read more
Prof David Thomas
Prof David Thomas

Precision Cancer Immunotherapy

The MoST program is also conducting clinical studies to test novel immunotherapy drugs in patients with high-mortality cancers.

‘Treatment strategies that select therapies based on immunological and molecular characteristics of tumours, rather than the organ and tissue of origin, create new opportunities for the treatment of uncommon or advanced cancers.’

Read more

The International Sarcoma Kindred Study

Sarcomas are rare, devastating cancers that arise anywhere in the body. The two main categories of sarcoma are soft tissue sarcomas, affecting mainly adults, and bone sarcomas, which are much more common in children and young adults.

‘The better we understand the genetic drivers that give a person an increased risk of cancer, the more precisely we can match individuals with the best possible treatment for them.’

Read more

National and International Collaborations

  • Asan Medical Center, Seoul, Korea
  • AstraZeneca, Cambridge, UK
  • Centre Georges François Leclerc, Dijon, France
  • Centre Régional de Lutte Contre le Cancer Léon Bérard, Lyon, France
  • Centre Régional de Lutte Contre le Cancer Oscar Lambret, Lille, France
  • Chris O’Brien Lifehouse, Sydney, Australia
  • Christchurch Hospital, New Zealand
  • Derriford Hospital, Plymouth, UK
  • Garvan Institute of Medical Research, Sydney, Australia
  • Hollywood Private Hospital, Perth, Australia
  • Hospitaux de Marseille, France
  • Huntsman Cancer Institute, University of Utah, USA
  • Institut Gustave Roussy, Villejuif, France
  • Mt Sinai Hospital, New York, USA
  • NHMRC Clinical Trials Centre, Sydney, Australia
  • Peter MacCallum Cancer Centre, Melbourne, Australia
  • Pfizer, New York, USA
  • Prince of Wales Hospital, Sydney, Australia
  • Princess Alexandra Hospital, Brisbane, Australia
  • Royal Adelaide Hospital, Australia
  • Royal Liverpool and Broadgreen University Hospital, Liverpool, UK
  • Royal Marsden Hospital, London, UK
  • Royal Prince Alfred Hospital, Melbourne, Australia
  • Sydney Children’s Hospital, Sydney, Australia
  • Tata Memorial Hospital, Mumbai, India
  • The Kinghorn Cancer Centre, Sydney, Australia
  • University College London Hospital, London, UK
  • Victorian Comprehensive Cancer Centre, Melbourne, Australia
  • Walter and Eliza Hall Institute, Melbourne, Australia.